Chemomab Therapeutics
CMMB
16 hedge funds and large institutions have $7.53M invested in Chemomab Therapeutics in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
7% more funds holding
Funds holding: 15 → 16 (+1)
5% more capital invested
Capital invested by funds: $7.14M → $7.53M (+$388K)
0.03% less ownership
Funds ownership: 0.4% → 0.36% (-0.03%)
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$22.8K |
| 2 |
WIA
Wetzel Investment Advisors
Indianapolis,
Indiana
|
+$15.8K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$15.3K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$10.3K |
| 5 |
GI
GAMMA Investing
Foster City,
California
|
+$8.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$470K |
| 2 |
YLHM
Yelin Lapidot Holdings Management
Tel Aviv,
Israel
|
-$104K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$62.7K |
| 4 |
HF
HRT Financial
New York
|
-$21K |
| 5 |
Millennium Management
New York
|
-$16.6K |
CMMB Hedge Fund Activity: Q4 2024 in Review
16 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q4 2024, worth a combined $7.53M — up 5.4% from $7.14M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CMMB positions and 4 closed out — a net gain of 1 holder — while 1 added to existing stakes and 6 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $22.8K. The largest seller was Morgan Stanley, cutting an estimated $470K.
- 16 institutional investors held Chemomab Therapeutics (CMMB) as of Q4 2024, up from 15 in Q3 2024.
- Funds reported $7.53M of Chemomab Therapeutics stock for Q4 2024, up 5.4% quarter-over-quarter.
- 5 funds opened new Chemomab Therapeutics positions in Q4 2024 and 4 closed out, a net change of +1 holder.
- The largest Chemomab Therapeutics buyer in Q4 2024 was Virtu Financial, an estimated $22.8K added.
- The largest Chemomab Therapeutics seller in Q4 2024 was Morgan Stanley, an estimated $470K sold.
Based on aggregated 13F filings for Q4 2024.